Abstract B016: Liquid biopsy biomarker analysis of a phase II trial of sacituzumab govitecan in castrate resistant metastatic prostate cancer
Jamie M. Sperger(University of Wisconsin–Madison), Joshua M. Lang(University of Wisconsin–Madison), Susan F. Slovin(Cornell University), Yue Shi(University of Wisconsin–Madison), Marina N. Sharifi(University of Wisconsin–Madison), Christos E. Kyriakopoulos(Dana-Farber Cancer Institute), Scott M. Dehm(University of Minnesota), Amy K. Taylor(University of Wisconsin–Madison), Matthew L. Bootsma(University of Wisconsin–Madison), Shuang G. Zhao(University of Wisconsin Carbone Cancer Center), Charlotte N. Stahlfeld(University of Wisconsin–Madison), Scott T. Tagawa(Cornell University), Katherine R. Kaufmann(University of Wisconsin–Madison), Kyle T. Helzer(University of Wisconsin–Madison)
Cited by 4
Related Papers
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
Prostate Cancer, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2019|1.6k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k